Submit a Review & Earn an Amazon Gift Card
You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!
Submit ReviewMcl-1 inhibitor; disrupts Mcl-1-Bim interaction and induces Mcl-1 proteasomal degradation. Exhibits no effect on Bcl-XL-Bim interaction. Selectively induces apoptosis in Mcl-1-dependent K562 leukemia cells. Sensitizes K562 and Raji cells to ABT-737-induced apoptosis.
分子量 | 510.15 |
公式 | C22H12Cl4N2O4 |
储存 | Store at -20°C |
纯度 | ≥97% (HPLC) |
CAS Number | 1227962-62-0 |
PubChem ID | 24797083 |
InChI Key | QYPJBTMRYKRTFG-UHFFFAOYSA-N |
Smiles | ClC1=C(Cl)C(N2C(C(C4=C(O)C=CC=C4)=O)=CC(Cl)=C2Cl)=C(C(C3=C(O)C=CC=C3)=O)N1 |
上方提供的技术数据仅供参考。批次相关数据请参见分析证书。
Tocris products are intended for laboratory research use only, unless stated otherwise.
参考文献是支持产品生物活性的出版物。
Doi et al (2012) Discovery of marinopyrrole A (maritoclax) as a selective Mcl-1 antagonist that overcomes ABT-737 resistance by binding to and targeting Mcl-1 for proteasomal degradation. J.Biol.Chem. 287 10224 PMID: 22311987
Pandey et al (2013) Proteasomal degradation of Mcl-1 by maritoclax induces apoptosis and enhances the efficacy of ABT-737 in melanoma cells. PLoS ONE 8 e78570 PMID: 24223823
关键词: Maritoclax, Maritoclax supplier, Mcl-1, inhibitors, inhibits, apoptosis, proapoptotic, leukemia, ABT737, marinopyrroleA, Bcl-2, Family, 5368, Tocris Bioscience
目前没有该产品的评论。 Be the first to review Maritoclax and earn rewards!
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*请注意,Tocris 仅会向正规科研企业/机构地址发送文献。
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.
There are two currently recognized forms of programmed cell death: apoptosis and necroptosis. This poster summarizes the signaling pathways involved in apoptosis, necroptosis and cell survival following death receptor activation, and highlights the influence of the molecular switch, cFLIP, on cell fate.